Impact of China on the Pharmaceutical Industry – Thematic Research

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The China pharma market size was US$149.8 billion in 2019 and the market is expected to grow at a CAGR of more than 12% between 2019 and 2029. China has the second largest pharma market in the world behind the US. The government has identified biopharma as a key industry for economic development. Recent regulatory reforms and national strategic initiatives are shifting focus from generics towards R&D innovation.

The impact of China on the pharmaceutical industry research report provides an assessment of the major industry, regulatory, macroeconomic, and technological trends shaping the Chinese pharma industry. The report also provides an overview of key regulatory and market access information, market drivers and barriers, and key players in the Chinese pharma sector.

Impact of China on the Pharmaceutical Industry

For more insights on the China pharma market forecast, download a free report sample

Key Trends in the China Pharma Market

The key trends that are impacting the China pharma market can be classified into industry trends, macroeconomic trends, technology trends, and regulatory trends.

  • Industry Trends: The key industry trends impacting the China pharma market include the dominance of generics, the expansion of biosimilars, the regenerative medicine sector, and others.
  • Macroeconomic Trends – The key macroeconomic trends that will shape the China pharma market are US-China relations and the improvement of the overall health of the people of China.
  • Technology Trends: The key technology trends impacting the China pharma market are the increasing use of AI in pharma, 5G, and the emerging 3D industry.
  • Regulatory Trends: The key regulatory trend impacting the China pharma market is the reforms to attract overseas companies. China has continually sought to make its market more accessible to international drug manufacturers and attract foreign companies by implementing multiple regulatory changes to allow for faster drug approval timelines and clearer guidelines

China Pharma Industry Analysis

The China pharma market size was US$149.8 billion in 2019, and as the innovation gap between China and other countries narrows, it is well positioned to increase its presence in the global market. The number of total deals per year in this sector has increased between 2011 to 2020, with the highest jump seen in 2020, fuelled by COVID-19.

China Pharma Industry Segmentation by Clinical Trials

The number of clinical trials in China has risen over the past decade. Oncology, central nervous system, infectious disease, genito urinary system and sex hormones, metabolic disorders, and others are the key types of clinical trials. The number of trials in oncology has seen the biggest growth from 2011 to 2020.

China Pharma Industry Analysis by Clinical Trials

China Pharma Industry Analysis by Clinical Trials

 For more insights on the clinical trials of China pharma industry, download a free report sample

China Pharma Industry Segmentation by Marketed Products

According to GlobalData’s Companies Database, there are more than 800 companies with drugs currently marketed in China. The key types of marketed drugs are generic, biosimilar, and innovator. Generic has the largest market share.

China Pharma Industry Analysis by Marketed Products

China Pharma Industry Analysis by Marketed Products

For more insights on the marketed products in the China pharma industry, download a free report sample

China Pharma Market Value Chain

In China, the pharmaceutical supply chain consists of primary and secondary manufacturing, market warehouses/distribution centers, wholesalers, retail shops/hospitals, and patients. Wholesalers, retailers, hospitals, and manufacturers   are   the   major distributors, but patients usually fill prescriptions in a hospital pharmacy for   convenience   and   quality assurance.

Leading Companies in the China Pharma Market

The leading companies in the China pharma market are Jiangsu Hengrui Medicine, Innovent Biologics, CSPC Pharmaceutical Group, Gan & Lee Pharmaceuticals, and others.

Key Themes Impacting the Pharmaceutical Industry

The key themes impacting the China pharma industry are mergers and acquisitions, 5G, augmented and virtual reality (AR & VR), artificial intelligence (AI), biosimilars, and immuno-oncology among others.

Key Themes Impacting the Pharmaceutical Industry

For more insights on the themes impacting the China pharma industry, download a free report sample

China Pharma Market Overview

Report Pages 117
Regions Covered China
Market Size (2019) $149.8 billion
CAGR (2019-2029) >12%
Key Trends Industry Trends, Technology Trends, Macroeconomic Trends, and Regulatory Trends
Key Clinical Trials Oncology, Central Nervous System, Infectious Disease, Genito Urinary System and Sex Hormones, Metabolic Disorders, and Others
Key Marketed Product Type Generic, Biosimilar, and Innovator
Value Chains Primary and Secondary Manufacturing, Market Warehouse/Distribution Centers, Wholesalers, Retail Shops/Hospitals, and Patients
Leading Companies Jiangsu Hengrui Medicine, Innovent Biologics, CSPC Pharmaceutical Group, Gan & Lee Pharmaceuticals, and Others

Scope

This report provides an assessment of the major industry, regulatory, macroeconomic, and technology trends shaping the Chinese pharma industry. It provides detailed analysis of deals, clinical trials, marketed and pipeline products, and contract manufacturing. It also provides an overview of key regulatory and market access information, market drivers and barriers, and key players in the Chinese pharma sector

Reasons to Buy

The report will help you to:

  • See what trends are shaping the Chinese pharma market and driving innovation, including key government policies and strategic initiatives.
  • See how emerging areas such as immuno-oncology, regenerative medicine, and biosimilars are developing.
  • Get an analysis of China’s strong manufacturing and outsourcing sector, including plans to further strengthen these capabilities.
  • See how emerging technologies such as 5G, artificial intelligence, and 3D printing are set to drive pharma innovation in China

Table of Contents

Table of Contents

Abbreviations

Related Reports

Executive Summary

• Key Findings

Introduction

• National Strategic Plans and Regulatory Reforms Are Driving Growth and Transformation of the Chinese Pharma Market

• Big Pharma Is Investing in China with Deals and Investment in R&D Centers

• Overview of Disease Prevalence in China

• Forecast Diagnosed Prevalence of Top Indications in China

• Key Influencer Twitter Chat Related to China

Trends

• The China Pharma Market Is Dominated By Generics

• The Biosimilars Market Is Set to Expand

• China Is Striving to Build Its Regenerative Medicine Sector

• China Is Also Building Its Immuno-Oncology Footprint

• China Has Strong Manufacturing and Outsourcing Capabilities

• Plans to Boost Manufacturing in West China

• Made in China 2025 Aims to Drive Further Manufacturing in China

• Drug Pricing Reforms to Increase Access to Innovative Drugs

• Medical Tourism Is Developing in China

• US-China Relations

• Shedding the Pharma Industry’s Poor Reputation in China

• Healthy China 2030 Aims to Improve the Overall Health of the Chinese Population

• Regulatory Reforms to Attract Overseas Companies

• China Is a Global Leader in 5G

• China’s Emerging 3D Printing Industry

Value Chain

Market Analysis

• China Pharma Market Expected to See Major Growth by 2029

• The Number of Pharma Deals in China Has Increased Since 2017

• Funding and Strategic Alliances Are Leading Deal Types in China

• Acquisitions Lead M&A Activity in China

• Top 10 M&A Deals 2018–2021: Chinese Companies

• Top 10 M&A Deals 2018–2021: International Companies

• Licensing Agreements and Oncology Dominate Strategic Partnerships

• Examples of Strategic Partnerships 2018–2021: Chinese Companies

• Examples of Strategic Partnerships 2018–2021: International Companies

• Financing Focuses on Biologics in Oncology across China

• Top Funding Deals 2018–2021: Chinese Entities

• Examples of Emerging Technology Deals 2018–2021

• China Pharma Market Jobs Analysis

Clinical Trials

• The Number of Clinical Trials in China Has Risen Over the Past Decade

• The Majority of Trials in China Are Early Phase

• Oncology Indications Dominate Clinical Trials in China

• The Majority of Clinical Trials in China Are Run by Chinese Entities

• Top 10 Clinical Trials Sites in China by Historical Volume

• Top 10 Clinical Trial Investigators in China by Historical Volume

• Top 10 Trials in China by Completed Enrollment Since 2019Marketed Products

• Most Marketed Drugs in China Are Developed by Chinese Companies

• Generics Have the Largest Share of Marketed Drugs in China

• China’s Position in the Global Generics Manufacturing Market

• Leading Generics Manufacturers in China

• Majority of Marketed Drugs Are for Bacterial Infections

• The Majority of Biologics Are Used to Treat Infectious Disease

• Most Companies Marketing Biologics in China Are Chinese

• Examples of China-Made Biologics (Innovator, Vaccines, etc.)

• Currently Approved COVID-19 Vaccines in China

• China Leads in Number of COVID-19 Vaccinations

• The Majority of Marketed Biosimilars Are Developed in China

• Examples of Marketed Biosimilars in China

• Many Marketed IO Drugs Are from International Companies

• Examples of Immuno-oncology Drugs from Chinese Companies

Pipeline Products

• Majority of Pipeline Drugs Are Developed by Chinese Companies

• Majority of Pipeline Drugs Are in Phase II or Lower, and Most Are Innovator Biologics

• Oncology Overwhelmingly Drives the Drug Pipeline in China

• Most Innovator Biologics and Biosimilars Are Also in the Oncology Space

• Examples of Late-Stage Pipeline Biologics in China

• Examples of Late-Stage Pipeline Biosimilars in China

• Regenerative Medicine Is a Rapidly Growing Sector in China

• Most Pipeline Regenerative Medicines Are in Early Stages of Development by Chinese Research Institutes

• The Highest Number of Regenerative Medicine Clinical Trials That Started in 2020 Were in China

• However, Phase II and Phase III Trials Have Been Impacted By A Gene-Editing Scandal

• Examples of Regenerative Medicines in China

• Domestic Companies Are Developing the Vast Majority of Novel Pipeline Immuno-oncology Drugs in China

• Majority of Pipeline Drugs Are in Phase II or Lower, and Most Are CAR-T Cell Therapies

• Examples of Late-Stage Pipeline Immuno-oncology Drugs

• Pipeline COVID-19 Vaccines and Treatments in China

• Examples of Pipeline COVID-19 Vaccines and Treatments

Contract Manufacturing in China

• Companies with Different Contacting Manufacturing Facilities in China

• China Is a Global Leader in API Chemical Manufacturing

• Outsourcing Deals for Biologic Manufacturing Are Increasing in China

• WuXi Has the Most CDMO Facilities and Has Forged the Most Outsourcing Deals in China

• West China Is Noticeably Lacking CDMO Facilities

• Examples of Contract Manufacturing Deals – Biosimilars/Biologics

• Examples of Contract Manufacturing Deals – Gene and Cell Therapy

• Examples of Contract Manufacturing Deals – COVID-19

Regulatory and Market Access

• Drug Approval Process in China

• Regulatory Reforms in China

• Regulation of Drugs in China

• Market Access for Drugs in China

Market Drivers and Barriers

• Market Drivers in China

• Market Barriers in China

Companies

Appendix

• Bibliography

• Key Themes Impacting the Pharmaceutical Industry

• Our Thematic Research Methodology

• About the Authors

• Contact Us

• Disclaimer

Frequently asked questions

Impact of China on the Pharmaceutical Industry – Thematic Research thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Impact of China on the Pharmaceutical Industry – Thematic Research was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Impact of China on the Pharmaceutical Industry – Thematic Research in real time.

  • Access a live Impact of China on the Pharmaceutical Industry – Thematic Research dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.